DLA Piper provided legal counsel to Triton Pacific Healthcare Partners (Triton Pacific) and ACON Investments in the transaction involving the sale of BioMatrix Specialty Infusion Pharmacy (BioMatrix) to Frazier Healthcare Partners. BioMatrix, headquartered in Florida, is a leading independent provider of specialty infusion services in the US.
The company focuses on delivering patient-centric care through therapeutic centers of excellence, offering management of various patient therapies such as IVIG, bleeding disorders, immunology, neurology, transplant, oncology, and rare diseases. Established in 2001, Triton Pacific is a private equity firm that caters to institutional and high net worth investors. Its healthcare division, Triton Pacific Healthcare Partners, boasts a dedicated team with a proven track record in healthcare investments. Joshua Kaye, the chair of DLA Piper’s US Healthcare sector, expressed optimism about the growth potential in infusion services and emphasized the firm's commitment to supporting clients in this evolving industry.
The DLA Piper team handling the deal included partners Sal Favuzza, Rachel Ludwig, and Jordan Bailowitz, along with associates Hunter Boyett and Mike Fehser. With a global team of over 225 lawyers specializing in private equity transactions, DLA Piper's Private Equity practice is well-equipped to provide comprehensive legal solutions to clients worldwide. Additionally, the firm's life sciences team is renowned for its expertise in assisting clients in the life sciences sector in transforming innovative ideas into successful businesses.
"We are witnessing substantial headwinds in support of infusion services. We look forward to continue working with clients investing in this emerging industry", said Joshua Kaye, chair of DLA Piper’s US Healthcare sector who led the deal team.
